Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tenalisib

Generic Name: Tenalisib

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₁₈FN_₅O_₂

CAS Number: 1639417-53-0

Unique Ingredient Identifier: 2261HH611H

Overview

Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib (RP6530)).

Background

Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib (RP6530)).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Phase 2

Recruiting

Posted: 2024/01/03

Sponsor:

Rhizen Pharmaceutica...

ID:NCT06189209

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Phase 2

Withdrawn

Posted: 2022/02/15

Sponsor:

Rhizen Pharmaceutica...

ID:NCT05239910

Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2

Completed

Posted: 2021/08/26

Sponsor:

Rhizen Pharmaceutica...

ID:NCT05021900

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Posted: 2019/12/18

Sponsor:

Rhizen Pharmaceutica...

ID:NCT04204057

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Phase 1

Completed

Posted: 2018/12/10

Sponsor:

Rhizen Pharmaceutica...

ID:NCT03770000

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy